[go: up one dir, main page]

MX2012012410A - Agente terapeutico y agente preventivo para enfermedad de alzheimer. - Google Patents

Agente terapeutico y agente preventivo para enfermedad de alzheimer.

Info

Publication number
MX2012012410A
MX2012012410A MX2012012410A MX2012012410A MX2012012410A MX 2012012410 A MX2012012410 A MX 2012012410A MX 2012012410 A MX2012012410 A MX 2012012410A MX 2012012410 A MX2012012410 A MX 2012012410A MX 2012012410 A MX2012012410 A MX 2012012410A
Authority
MX
Mexico
Prior art keywords
alzheimer
disease
agent
preventative
therapeutic agent
Prior art date
Application number
MX2012012410A
Other languages
English (en)
Inventor
Kaoru Nakao
Yohei Miyamoto
Naohiro Yamada
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2012012410A publication Critical patent/MX2012012410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a un agente terapéutico y agente preventivo para la enfermedad de Alzheimer que tienen una acción sobre el progreso de la enfermedad de Alzheimer y mantener un efecto sobre la enfermedad de Alzheimer aún con la administración a largo plazo. Se describe específicamente un agente terapéutico y un agente preventivo para la enfermedad de Alzheimer que contiene un derivado de ciclohexano representado por la fórmula (3), una sal del mismo farmacológicamente aceptable, o un profármaco del mismo como el ingrediente activo.
MX2012012410A 2010-04-28 2011-04-28 Agente terapeutico y agente preventivo para enfermedad de alzheimer. MX2012012410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010103246 2010-04-28
PCT/JP2011/060355 WO2011136318A1 (ja) 2010-04-28 2011-04-28 アルツハイマー病の治療剤又は予防剤

Publications (1)

Publication Number Publication Date
MX2012012410A true MX2012012410A (es) 2012-12-17

Family

ID=44861614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012410A MX2012012410A (es) 2010-04-28 2011-04-28 Agente terapeutico y agente preventivo para enfermedad de alzheimer.

Country Status (13)

Country Link
US (1) US8598212B2 (es)
EP (1) EP2565184B8 (es)
JP (1) JP5682555B2 (es)
KR (1) KR101739881B1 (es)
CN (1) CN102858748B (es)
AU (1) AU2011246026B2 (es)
BR (2) BR112012024346A2 (es)
CA (1) CA2793859C (es)
ES (1) ES2560220T3 (es)
MX (1) MX2012012410A (es)
PL (1) PL2565184T3 (es)
RU (1) RU2560171C2 (es)
WO (1) WO2011136318A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6447496B2 (ja) * 2014-01-29 2019-01-09 東レ株式会社 多発性硬化症の治療剤又は予防剤
WO2018181859A1 (ja) * 2017-03-31 2018-10-04 東レ株式会社 抗がん剤誘発末梢神経障害の治療剤又は予防剤
KR102696318B1 (ko) 2021-04-23 2024-08-20 주식회사 알트메디칼 이소퀴놀린 유도체 화합물을 유효성분으로 포함하는 미토콘드리아 기능이상으로 인한 질환의 예방 또는 치료용 조성물
US12194671B2 (en) 2021-07-30 2025-01-14 Canon Kabushiki Kaisha Information processing apparatus, molding apparatus, molding method, and article manufacturing method

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007996A2 (en) 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
AU4308300A (en) 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
JP2003503456A (ja) 1999-07-02 2003-01-28 スチュアート エイ． リプトン 神経傷害またはアポトーシスを軽減する方法
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
CA2439593C (en) * 2001-04-05 2010-02-09 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
US20040138296A1 (en) * 2002-08-12 2004-07-15 Pharmacia Corporation Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease
JP2006503025A (ja) * 2002-09-05 2006-01-26 サイオス インク． ｐ３８ＭＡＰキナーゼの抑制による疼痛治療
WO2007111323A1 (ja) 2006-03-27 2007-10-04 Toray Industries, Inc. ウレイド誘導体およびその医薬用途
WO2008105383A1 (ja) 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
WO2011125836A1 (ja) * 2010-03-31 2011-10-13 東レ株式会社 線維筋痛症の治療剤又は予防剤

Also Published As

Publication number Publication date
EP2565184A1 (en) 2013-03-06
KR101739881B1 (ko) 2017-05-25
PL2565184T3 (pl) 2016-06-30
EP2565184A4 (en) 2013-09-11
KR20130064717A (ko) 2013-06-18
ES2560220T3 (es) 2016-02-17
AU2011246026A1 (en) 2012-11-29
EP2565184B1 (en) 2015-12-30
WO2011136318A1 (ja) 2011-11-03
CA2793859A1 (en) 2011-11-03
JP5682555B2 (ja) 2015-03-11
CA2793859C (en) 2018-02-13
AU2011246026B2 (en) 2014-10-30
RU2560171C2 (ru) 2015-08-20
CN102858748B (zh) 2015-06-17
BR122021002784B1 (pt) 2021-08-31
EP2565184B8 (en) 2016-03-09
RU2012150842A (ru) 2014-06-10
US20130041158A1 (en) 2013-02-14
JPWO2011136318A1 (ja) 2013-07-22
BR112012024346A2 (pt) 2016-05-24
CN102858748A (zh) 2013-01-02
US8598212B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MY174339A (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
TN2012000092A1 (en) Therapeutic agent for mood disorders
PH12014500386A1 (en) Combination treatment for hepatitis c
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
TN2016000489A1 (en) Carboxamide derivatives.
NZ596362A (en) Therapeutic agent for motor disorders
MX362830B (es) Agente terapeutico o profilactico para enfermedades del tracto biliar.
TN2016000491A1 (en) Carboxamide derivatives.
TN2014000060A1 (en) Benzothiazolone compound
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.
TN2012000093A1 (en) Therapeutic agent for anxiety disorders
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
IN2013DE00880A (es)
PH12016502247A1 (en) Carboxamide derivatives
WO2013035997A3 (en) Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt

Legal Events

Date Code Title Description
FG Grant or registration